What is CAGR? What does CAGR table indicate for Strides Pharma Science Ltd?

Compounded average growth rate (CAGR) measures the average annual growth rate compounded year-on-year over a period of time.

Strides Pharma Science Ltd Stock Analysis

Mid Cap

Evaluated by 2651 users | BSE: 532531 | NSE: STAR |
Pharmaceuticals & Drugs

10 Year X-Ray

Standalone basis Standalone basis P Consolidated basis P

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

What is a Financial Track Record? How to read this chart in order to understand the data present here?

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Strides Pharma Science Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

	Dec'10	Dec'11	Dec'12	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20
Return on Capital Employed	4.68%	5.61%	8.53%	21.65%	9.19%	6.55%	2.06%	21.86%	3.99%	4.11%

Growth Parameters	Growth Parameters Colour Code Guide

Net Sales (Rs. Cr.)	505	750	712	851	929	2,222	1,382	1,955	1,537	1,674
Y-o-Y Gr. Rt.	-	48.5%	-5%	19.5%	9.2%	139%	-37.8%	41.5%	-21.4%	8.9%
Adjusted EPS (Rs.)	6.92	13.91	22.41	49.86	26.67	16.08	5.36	98.72	13.24	13.36
Y-o-Y Gr. Rt.	-	101%	61.1%	122.5%	-46.5%	-39.7%	-66.7%	1741.8%	-86.6%	0.9%
Book Value per Share (Rs.)	243.14	232.35	232.62	219.01	247.18	352.77	360.5	352.29	362.84	353.87
Adjusted Net Profit	40	81.2	132	297	159	144	47.9	884	119	120
Net Op. Cash Flow (Rs. Cr.)	48.1	102	11.1	-2.7	207	83.1	412	65.6	40	149
Debt to Cash Flow from Ops	25.82	8.8	56.95	-141.26	1.95	18.59	3.91	9.24	20.25	5.73

Difference between Standalone Basis and Consolidated basis? Which method is preferred for Strides Pharma Science Ltd. ?

Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.

Strides Pharma Science Ltd. should be analysed on a Standalone basis

CAGR CAGR Colour Code Guide

	9 yrs	5 yrs	3 yrs	1 yr
Net Sales	14.3%	12.5%	6.6%	8.9%
Adjusted EPS	7.6%	-12.9%	35.6%	0.9%
Book Value per Share	4.3	7.4	-0.6	-2.5
Share Price	3.5%	-3.5%	10.4%	162.8%

Key Financial Parameter	Performance Ratio Colour Code Guide

	Dec'10	Dec'11	Dec'12	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20
Return on Equity (%)	3.43	5.87	9.65	24.73	10.23	6.2	1.5	27.63	3.69	3.72
Operating Profit Margin (%)	14.55	20.32	19.6	17	14.41	12.14	8.1	7.36	9.82	13.46
Net Profit Margin (%)	7.92	10.83	18.51	34.9	17.09	6.47	3.47	45.18	7.71	7.15
Debt to Equity	0.89	0.66	0.46	0.29	0.27	0.49	0.5	0.19	0.25	0.27
Working Capital Days	861	933	726	464	783	293	405	295	383	343
Cash Conversion Cycle	40	39	79	75	91	57	123	39	93	112

Management X-Ray

Shareholding Pattern

Entity	Percentage Holding
Promoters	29.67%
Institutions	40.90%
Non-Institutions	29.42%

Promoter's Holding & Share Pledging

Pledged ^*

28.91

16.31

13.02

51.29

48.20

50.93

46.84

37.04

40.38

32.56

* Pledged shares as % of Promoter's holding (%)

FAQs

1. Is Strides Pharma Science Ltd a good quality company?

MoneyWorks4Me analysed the past 10-year performance of Strides Pharma Science Ltd and arrived at the following conclusion:

Past 10 year's financial track record indicates that Strides Pharma Science Ltd is a below average quality company. However, for specific investment actions please connect with your investment advisor.

2. Is current market price of Strides Pharma Science Ltd a good price to buy it?

The 5-year analysis of Strides Pharma Science Ltd's performance infers:

Strides Pharma Science Ltd earnings have declined by -12.9%, whereas share price has depreciated -3.5% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

3. What is Strides Pharma Science Ltd share price return in the past 10 years ?

We analysed the performance of Strides Pharma Science Ltd share prices over the last 10 years. Here is what we found out:

Strides Pharma Science Ltd share price has depreciated 8.4% annually over the past ten years.

About Company

Strides Pharma Science Limited, incorporated in 1990, is a global pharmaceutical company headquartered in Bangalore, India. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. Strides has a global manufacturing footprint with eight manufacturing facilities spread across four continents, including five US FDA approved facilities and two facilities for the rest of world markets. The Company has a dedicated R&D facility

Business area of the company

The company’s core competence is in the development and manufacture of wide range of niche and technically complex pharmaceutical products. The company is also among the world's largest soft gelatin capsule manufacturers.

Products

Soft gel capsules - The company manufactures range of soft gel in category of nutraceuticals, Rx, specialty OTCs and immunosuppressants.

Steriles- Under this, it offers its products in therapeutic segments that includes beta-lactams and cephalosporins. The company manufactures striles in various forms such as prefill syringes, ampoules, vials and penicillins.

Awards

2017-18

Received several customer award including the Cardinal Health Supply Chain Excellence Award for 2017

2019-20

The Global Presence Award
Foreign owned business Award

Milestones

2013

Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet.
Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility.
Strides announces WHO pre-qualification for Artemether + Lumifantrine -StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology.
Strides Arcolab - Re-branding Biotech Business as ''Stelis''.
Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market.

2014

Medicines for Malaria Venture announces collaborations with Cipla and Strides.
Strides Arcolab makes strategic investment in Oncobiologics Inc., USA.
Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries.
Strides Arcolab receives US FDA approval for Buspirone Tablets.
Strides Arcolab receives US FDA approval for Calcitriol Softgel.
Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna.
Strides Arcolab to acquire Shasun Pharma in all stock deal.

2015

Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company's Public Relations Agenc
Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc,
Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India ''Virso''
Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350 -Strides Arcolab gets USFDA nod for HIV treatment drug
Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company.
Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia.
Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy
Strides Arcolab Ltd has changed from its present name ''Strides Arcolab Limited'' to Strides Shasun Limited

2016

Strides Shasun updates on ''Acquisition of seven brands from Johnson & Johnson''.
Strides Shasun update on ''Acquisition of CNS divisions of erstwhile Ranbaxy''. -''Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia.
Strides Shasun to acquire controlling stake in Universal Corporation, Kenya.
Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet.
Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore.

2017-18

Launched consumer health division in a difficult market environment.
Product filing and approval gained momentum with 12 new ANDA filings and 14 product approvals received
Witnessed single-digit price erosion for front-end portfolio

2018-19

Re-launched erstwhile partnership molecules through front-end business witnessing encouraging traction which contributed to a sequential ramp-up in the US business.
Completed acquisition of Vensun Pharmaceuticals and took 100% ownership in a joint venture with Vivimed Labs adding ~US$ 25 million additional sales and a combined portfolio of 100+ ANDAs.
Entered into a strategic partnership with SUDA Pharmaceuticals for an exclusive agreement for novel and a fast-acting oral spray of sumatriptan in the US market.

2019-20

Increased production capacity up to 1.4 Billion tablets annually on single shift operations, with new equipment-like continuous coater, high speed automatic inspection machine-and technology - for manufacturing hot molten liquid fill into a hard gelatin capsule
Successfully transferred eight products of which three are approved by the US FDA; the remaining five products are expected to receive US FDA approval within the next six months.
Implemented Manufacturing Execution System (MES) in processing facility, with integrated electronic batch record.
Installed packaging serialization and automated materials tracking system (GEM-MT).
Equipped the unit with laser-based, high-end inspection system for scanning tablets and capsules with 3D cameras, which can identify defects as low as 20 microns leading to a high level of automated quality controls.
Launched two products from the Singapore unit under the procurements administered by the Department of Veteran Affairs (VA) in the US, based on its eligibility as a designated country.
Initiated transfer of eight new products to be manufactured in the Singapore unit.

Read Less